JPMorgan lowered the firm’s price target on Zimmer Biomet to $120 from $125 and keeps a Neutral rating on the shares. The analyst updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $112 from $117 at Truist
- Zimmer Biomet price target lowered to $115 from $120 at Canaccord
- Zimmer Biomet price target lowered to $110 from $112 at Wells Fargo
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Zimmer Biomet initiated with a Peer Perform at Wolfe Research